{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:11:37Z","timestamp":1790068297154,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"vor","delay-in-days":1554,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1593\/tlo.09244","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T09:49:46Z","timestamp":1395740986000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells"],"prefix":"10.1016","volume":"3","author":[{"given":"Erina","family":"Vlashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcom","family":"Mattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chann","family":"Lagadec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza Della","family":"Donna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany M.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polin","family":"Nikolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Pajonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1593\/tlo.09244_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1593\/tlo.09244_bib2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nature02263","article-title":"Protein degradation and protection against misfolded or damaged proteins","volume":"426","author":"Goldberg","year":"2003","journal-title":"Nature"},{"key":"10.1593\/tlo.09244_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/bjc.1998.71","article-title":"The ubiquitin-proteasome pathway in cancer","volume":"77","author":"Spataro","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1593\/tlo.09244_bib4","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1016\/j.febslet.2005.03.042","article-title":"The regulation of proteasome degradation by multiubiquitin chain binding proteins","volume":"579","author":"Miller","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1593\/tlo.09244_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1667\/0033-7587(2001)156[0447:TPICBA]2.0.CO;2","article-title":"The proteasome in cancer biology and treatment","volume":"156","author":"Pajonk","year":"2001","journal-title":"Radiat Res"},{"key":"10.1593\/tlo.09244_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1593\/tlo.09244_bib7","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1593\/tlo.09244_bib8","first-page":"99","article-title":"Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells","volume":"7","author":"Pedeboscq","year":"2008","journal-title":"J Exp Ther Oncol"},{"key":"10.1593\/tlo.09244_bib9","first-page":"1283","article-title":"Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts","volume":"20","author":"Labussiere","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1593\/tlo.09244_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.08.050","article-title":"Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies","volume":"74","author":"Kubicek","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1593\/tlo.09244_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1593\/tlo.09244_bib12","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J Med Chem"},{"key":"10.1593\/tlo.09244_bib13","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","article-title":"The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia","volume":"5","author":"Ruiz","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1593\/tlo.09244_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjc.6603406","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1593\/tlo.09244_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1593\/tlo.09244_bib16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"10.1593\/tlo.09244_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1593\/tlo.09244_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2407-5-76","article-title":"The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism","volume":"5","author":"Pajonk","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1593\/tlo.09244_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1593\/neo.06634","article-title":"The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinomacells after cyclic hypoxia\/reoxygenation from ionizing radiation","volume":"8","author":"Pajonk","year":"2006","journal-title":"Neoplasia"},{"key":"10.1593\/tlo.09244_bib20","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res"},{"key":"10.1593\/tlo.09244_bib21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0360-3016(00)00516-2","article-title":"Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition","volume":"47","author":"Pajonk","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1593\/tlo.09244_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00000421-200110000-00013","article-title":"Molecular pathways that modify tumor radiation response","volume":"24","author":"Pervan","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1593\/tlo.09244_bib23","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ejca.2008.05.022","article-title":"Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours","volume":"44","author":"Cresta","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1593\/tlo.09244_bib24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/sj.bjc.6605043","article-title":"Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor","volume":"100","author":"Dudek","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1593\/tlo.09244_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10637-008-9154-z","article-title":"A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy","volume":"27","author":"Lieu","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1593\/tlo.09244_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.onc.1208225","article-title":"Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)","volume":"24","author":"Yin","year":"2005","journal-title":"Oncogene"},{"key":"10.1593\/tlo.09244_bib27","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ijrobp.2007.07.2366","article-title":"Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines","volume":"69","author":"van Nifterik","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1593\/tlo.09244_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","article-title":"PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells","volume":"4","author":"Bleau","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1593\/tlo.09244_bib29","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1158\/1535-7163.MCT-07-2198","article-title":"Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation","volume":"7","author":"Tomioka","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1593\/tlo.09244_bib30","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ijrobp.2007.11.069","article-title":"Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)\/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1593\/tlo.09244_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0360-3016(99)00539-8","article-title":"Survival of human glioma cells treated with various combination of temozolomide and x-rays","volume":"47","author":"van Rijn","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1593\/tlo.09244_bib32","first-page":"309","article-title":"Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer","volume":"5","author":"Baker","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1593\/tlo.09244_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-004-0811-4","article-title":"Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line","volume":"54","author":"Mortenson","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1593\/tlo.09244_bib34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ctrv.2008.03.125","article-title":"DNA repair and cancer stem-like cells\u2014potential partners in glioma drug resistance?","volume":"34","author":"Johannessen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1593\/tlo.09244_bib35","first-page":"5002","article-title":"The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells","volume":"58","author":"Furnari","year":"1998","journal-title":"Cancer Res"},{"key":"10.1593\/tlo.09244_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djn509","article-title":"In-vivo imaging, tracking, and targeting of cancer stem cells","volume":"101","author":"Vlashi","year":"2009","journal-title":"J Natl Cancer Inst"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523310800439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523310800439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:27:50Z","timestamp":1761834470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523310800439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1936523310800439"],"URL":"https:\/\/doi.org\/10.1593\/tlo.09244","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1593\/tlo.09244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Neoplasia Press, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}